Timeline Snapshot
physicians discussing cases
Timeline Snapshot
05/07/2026
April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
05/07/2026
FDA Approval
FDA Approval
05/04/2026
Anthony Calabro, MA
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
05/04/2026
FDA Approval
FDA Approval
05/04/2026
Anthony Calabro, MA
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
05/04/2026
FDA Approval
FDA Approval
05/04/2026
Anthony Calabro, MA
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
05/04/2026
FDA Approval
FDA Approval
05/04/2026
Anthony Calabro, MA
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
05/04/2026
FDA Approval
FDA Approval
05/04/2026
Anthony Calabro, MA
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
05/04/2026
FDA Approval
FDA Approval
05/04/2026
Anthony Calabro, MA
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
05/04/2026
FDA Approval
FDA Approval
05/04/2026
Anthony Calabro, MA
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
05/04/2026
FDA Approval
FDA Approval
05/04/2026
Anthony Calabro, MA
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
05/04/2026
FDA Alert
FDA Alert
05/01/2026
Anthony Calabro, MA
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
05/01/2026